DE69721006D1 - Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen - Google Patents

Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen

Info

Publication number
DE69721006D1
DE69721006D1 DE69721006T DE69721006T DE69721006D1 DE 69721006 D1 DE69721006 D1 DE 69721006D1 DE 69721006 T DE69721006 T DE 69721006T DE 69721006 T DE69721006 T DE 69721006T DE 69721006 D1 DE69721006 D1 DE 69721006D1
Authority
DE
Germany
Prior art keywords
blood
autoimmune diseases
modified
treatment
aliquot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69721006T
Other languages
English (en)
Other versions
DE69721006T2 (de
Inventor
E Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9617611.0A external-priority patent/GB9617611D0/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of DE69721006D1 publication Critical patent/DE69721006D1/de
Application granted granted Critical
Publication of DE69721006T2 publication Critical patent/DE69721006T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/32—Oxygenators without membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
DE69721006T 1996-08-22 1997-08-11 Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen Expired - Fee Related DE69721006T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9617611 1996-08-22
GBGB9617611.0A GB9617611D0 (en) 1996-08-22 1996-08-22 Treatment of autoimmune disease
US754348 1996-11-22
US08/754,348 US5980954A (en) 1992-02-07 1996-11-22 Treatment of autoimmune diseases
PCT/CA1997/000564 WO1998007436A1 (en) 1996-08-22 1997-08-11 Treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
DE69721006D1 true DE69721006D1 (de) 2003-05-22
DE69721006T2 DE69721006T2 (de) 2004-01-22

Family

ID=26309905

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69721006T Expired - Fee Related DE69721006T2 (de) 1996-08-22 1997-08-11 Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen

Country Status (12)

Country Link
US (2) US5980954A (de)
EP (1) EP0920322B9 (de)
JP (1) JP3883013B2 (de)
AT (1) ATE237339T1 (de)
AU (1) AU724265B2 (de)
CA (1) CA2263911C (de)
DE (1) DE69721006T2 (de)
DK (1) DK0920322T3 (de)
ES (1) ES2199367T3 (de)
NZ (1) NZ334635A (de)
PT (1) PT920322E (de)
WO (1) WO1998007436A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617611D0 (en) * 1996-08-22 1996-10-02 Vasogen Inc Treatment of autoimmune disease
US6669965B2 (en) * 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6066489A (en) 1996-08-30 2000-05-23 Arrow International, Inc. Method for treating blood borne viral pathogens such as immunodeficiency virus
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
AU741181B2 (en) * 1997-09-12 2001-11-22 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal Treatment of stress and preconditioning against stress
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
WO2000029003A2 (en) * 1998-11-13 2000-05-25 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
WO2000041705A1 (en) * 1999-01-12 2000-07-20 Vasogen Ireland Limited Pre-conditioning against cell death
CA2269364A1 (en) * 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2381730A1 (en) * 1999-09-16 2001-03-22 Vasogen Ireland Limited Apparatus and process for conditioning mammalian blood
JP2003510284A (ja) * 1999-09-24 2003-03-18 バソジェン アイルランド リミテッド アテローム性動脈硬化症の処置のための併用療法
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2297448A1 (en) * 2000-01-28 2001-07-28 Vasogen Inc. Improved inhibition of graft versus host disease
US6800300B1 (en) 2000-03-31 2004-10-05 Vasogen Ireland Limited Method for treating autoimmune and alloimmune diseases
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6970740B2 (en) * 2000-04-19 2005-11-29 Clemson University UVC rediation therapy for leukemia
US6585676B1 (en) * 2000-04-19 2003-07-01 Clemson University UVC radiation therapy for chronic lymphocytic leukemia
CA2308105A1 (en) * 2000-05-11 2001-11-11 Vasogen Ireland Limited Treatment of il-10 deficiencies
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2324199A1 (en) * 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
US20020090360A1 (en) * 2000-12-05 2002-07-11 Bolton Anthony E. Inflammatory cytokine secretion inhibition
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
CA2327630A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Transforming growth factor regulation
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
EP1990055A3 (de) * 2001-11-29 2011-11-16 Therakos, Inc. Verfahren zur Vorbehandlung einer Person durch extrakorporale Photopherese und/oder apoptotische Zellen
US20050244298A1 (en) * 2002-04-10 2005-11-03 Smith Eldon R Electrocardiographic aspects of chf treatment
JP3927922B2 (ja) * 2003-05-21 2007-06-13 Ｙｋｋ株式会社 スライドファスナー用スプリング体及び同スプリング体が装着されたスライダー
US7368542B2 (en) 2003-06-09 2008-05-06 Redox-Reactive Reagents Llc Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US20050189302A1 (en) * 2003-07-31 2005-09-01 Latino Joseph S. Viral inactivation using ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US7736494B2 (en) * 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
WO2005025712A2 (en) * 2003-07-31 2005-03-24 Lipidviro Tech Viral inactivation using ozone
TR201816556T4 (tr) * 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
WO2006115509A2 (en) * 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006007710A2 (en) * 2004-07-20 2006-01-26 Vasogen Ireland Limited Acute inflammatory condition treatment
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
US20090232834A1 (en) * 2005-07-18 2009-09-17 Al-Harbi Saleh A Methods and Agents to Treat Autoimmune Diseases
US8518649B2 (en) * 2007-04-04 2013-08-27 {hacek over (S)}árka O. Southern Systems and methods for analyzing persistent homeostatic perturbations
US8951561B2 (en) * 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
WO2015195896A1 (en) 2014-06-19 2015-12-23 Immunolight, Llc Methods and systems for treating cell proliferation disorders with psoralen derivatives
US20090104212A1 (en) * 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
KR101322247B1 (ko) * 2007-09-06 2013-10-25 삼성전자주식회사 진공청소기용 흡입브러시 및 그 높이조절방법
CA3095369C (en) 2008-04-04 2023-09-26 Immunolight, Llc Non-invasive systems and methods for in-situ photobiomodulation
EP2729175B1 (de) 2011-07-08 2021-12-01 Duke University System zur lichtstimulation in einem medium
ITMI20131667A1 (it) * 2013-10-09 2015-04-10 Ind Paolo Gobbi Frattini Metodo per pre-trattare le cellule ematiche prima della separazione.
WO2015112850A2 (en) 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068428C2 (de) 1957-05-21 1960-04-21 Hermann Dr Med Jentjens Verfahren und Einrichtung zur Herstellung von oxygeniertrm Blut
US3715430A (en) * 1969-08-04 1973-02-06 E Ryan Purified oxygen gas containing ozone and higher oxygen polymers
US3925344A (en) 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
FR2528848A1 (fr) 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4695647A (en) 1984-03-22 1987-09-22 Drug Science Foundation Aromatic derivatives of 13-azaprostanoic acid
US4659726A (en) 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
DD249143A3 (de) * 1985-03-20 1987-09-02 Ilmenau Tech Hochschule Vorrichtung zur physiologisch-therapeutisch wirksamen optischen bestrahlung koerpereigenen venenblutes
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
US4632980A (en) * 1985-04-03 1986-12-30 Immunologics Ozone decontamination of blood and blood products
US5194590A (en) 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
DE8704467U1 (de) * 1987-01-15 1988-05-26 Quarzlampenfabrik Dr.-Ing. Felix W. Mueller Gmbh & Co Kg, 4300 Essen, De
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0339924B1 (de) * 1988-04-29 1995-03-29 Medizone International, Inc. Vorrichtung für die gesteuerte Generierung und Verabreichung von Ozon
US4983637A (en) 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5591457A (en) 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
AU3506293A (en) 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
AU681999B2 (en) 1992-02-07 1997-09-18 Vasogen Ireland Limited Method of increasing the concentration of nitric oxide in blood
NZ306395A (en) 1995-05-05 2000-02-28 Vasogen Inc Treatment of blood to remove symptoms of vascular disorders by elevation of temperature, ultraviolet radiation or treatment with an oxidative environment
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals

Also Published As

Publication number Publication date
NZ334635A (en) 2000-08-25
AU724265B2 (en) 2000-09-14
EP0920322B9 (de) 2003-10-29
WO1998007436A1 (en) 1998-02-26
DE69721006T2 (de) 2004-01-22
CA2263911C (en) 2007-01-16
AU3844297A (en) 1998-03-06
JP3883013B2 (ja) 2007-02-21
PT920322E (pt) 2003-11-28
US5980954A (en) 1999-11-09
US6569467B1 (en) 2003-05-27
EP0920322B1 (de) 2003-04-16
JP2000517302A (ja) 2000-12-26
EP0920322A1 (de) 1999-06-09
CA2263911A1 (en) 1998-02-26
ATE237339T1 (de) 2003-05-15
DK0920322T3 (da) 2003-08-04
ES2199367T3 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
DE3684363D1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE3685853T2 (de) Mittel zur behandlung von knochenkrankheiten.
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
FI913818A0 (fi) Nytt trombolytiskt aemne.
ATE366581T1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
ATE99669T1 (de) N-2,3-butadienyl-tri-aminoalkanderivate.
ATE246929T1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
ATE422857T1 (de) Induktion von immunologischer toleranz
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
GB9617611D0 (en) Treatment of autoimmune disease
ATE316789T1 (de) Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
SU833247A1 (ru) Способ лечени заболеваний,вызван-НыХ уКуСОМ КлЕщЕй
Grant DUHIKYA: THE HOPI HEALER.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
UA37041A (uk) Спосіб стимуляції функціональної активності т-лімфоцитів
Africa An Act (No. 65 of 1983) to provide for the donation or the making available of human bodies and tissue for the purposes of medical or dental training, research or therapy or the advancement of medicine or dentistry in general; for the post-mortem examination of certain human bodies; for the removal of tissue, blood and gametes from the bodies of living persons and the use thereof for medical or dental purposes; for the control of the artificial insemination of persons; and for the regulation of the import and export of human tissue, blood and gametes; and to provide for matters connected therewith. Date of commencement: 12 July 1985 (the Human Tissue Act, 1983)
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
IT8530823V0 (it) Lettino terapeutico per la cura dei reumatismi ed alcune allergie attraverso il vapore balsamico agente sull'epidermide, sui muscoli e sul corpo del paziente.
UA42404A (uk) Спосіб детоксикації організму

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee